GUIDED THERAPEUTICS, INC. Financials Guided Therapeutics, Inc.
Equities
GTHP
US40171F5017
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.09 USD | -10.00% |
|
-5.26% | -41.37% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 0.5946 | 0.4415 | 3.928 | 7.91 | 14.58 | 8.305 |
| Enterprise Value (EV) 1 | 5.692 | 5.561 | 8.151 | 10.17 | 14.53 | 9.772 |
| P/E ratio | 17.4 x | -0.23 x | -7.5 x | -3.19 x | -1.96 x | -2.09 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 10.4 x | 12.3 x | 38.5 x | 97.7 x | 1,121 x | 84.7 x |
| EV / Revenue | 99.9 x | 154 x | 79.9 x | 126 x | 1,118 x | 99.7 x |
| EV / EBITDA | -3.74 x | -6.07 x | -7.91 x | -4.31 x | -4.36 x | -2.83 x |
| EV / FCF | -2.8 x | -13.6 x | -3.22 x | -4.61 x | -12.6 x | -9.89 x |
| FCF Yield | -35.7% | -7.34% | -31% | -21.7% | -7.93% | -10.1% |
| Price to Book | -0.02 x | -0.02 x | -0.29 x | -0.64 x | -2.44 x | -1.22 x |
| Nbr of stocks (in thousands) | 2,478 | 3,319 | 13,096 | 13,634 | 48,596 | 54,105 |
| Reference price 2 | 0.2400 | 0.1330 | 0.2999 | 0.5802 | 0.3000 | 0.1535 |
| Announcement Date | 5/8/19 | 4/20/20 | 4/7/21 | 3/30/22 | 3/30/23 | 3/28/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.057 | 0.036 | 0.102 | 0.081 | 0.013 | 0.098 |
| EBITDA 1 | -1.521 | -0.916 | -1.031 | -2.361 | -3.329 | -3.448 |
| EBIT 1 | -1.548 | -0.937 | -1.052 | -2.362 | -3.333 | -3.457 |
| Operating Margin | -2,715.79% | -2,602.78% | -1,031.37% | -2,916.05% | -25,638.46% | -3,527.55% |
| Earnings before Tax (EBT) 1 | 1.016 | -1.921 | -0.279 | -2.07 | -4.341 | -3.489 |
| Net income 1 | 1.016 | -1.921 | -0.279 | -2.07 | -4.341 | -3.489 |
| Net margin | 1,782.46% | -5,336.11% | -273.53% | -2,555.56% | -33,392.31% | -3,560.2% |
| EPS 2 | 0.0138 | -0.5818 | -0.0400 | -0.1817 | -0.1530 | -0.0735 |
| Free Cash Flow 1 | -2.032 | -0.4081 | -2.528 | -2.204 | -1.152 | -0.9884 |
| FCF margin | -3,565.57% | -1,133.68% | -2,477.94% | -2,720.99% | -8,860.58% | -1,008.55% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/8/19 | 4/20/20 | 4/7/21 | 3/30/22 | 3/30/23 | 3/28/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 5.1 | 5.12 | 4.22 | 2.26 | - | 1.47 |
| Net Cash position 1 | - | - | - | - | 0.05 | - |
| Leverage (Debt/EBITDA) | -3.351 x | -5.59 x | -4.096 x | -0.9555 x | - | -0.4255 x |
| Free Cash Flow 1 | -2.03 | -0.41 | -2.53 | -2.2 | -1.15 | -0.99 |
| ROE (net income / shareholders' equity) | -5.77% | 11.7% | 2.01% | 25.4% | 104% | 104% |
| ROA (Net income/ Total Assets) | -301% | -82.7% | -52% | -87.1% | -77.1% | -85.8% |
| Assets 1 | -0.3371 | 2.322 | 0.5368 | 2.377 | 5.633 | 4.065 |
| Book Value Per Share 2 | -15.20 | -5.340 | -1.030 | -0.9000 | -0.1200 | -0.1300 |
| Cash Flow per Share | - | 0.2700 | 0.0100 | 0.0500 | 0.0500 | 0.0100 |
| Capex | - | - | 0 | 0.01 | 0.03 | - |
| Capex / Sales | - | - | 0.98% | 17.28% | 238.46% | - |
| Announcement Date | 5/8/19 | 4/20/20 | 4/7/21 | 3/30/22 | 3/30/23 | 3/28/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -41.37% | 5.02M | |
| +12.15% | 227B | |
| +14.90% | 197B | |
| +18.22% | 141B | |
| +29.15% | 110B | |
| +0.53% | 64.15B | |
| +16.92% | 53.72B | |
| +6.33% | 51.75B | |
| +10.93% | 45.2B | |
| +5.87% | 37.37B |
- Stock Market
- Equities
- GTHP Stock
- Financials Guided Therapeutics, Inc.
